NovoCure Limited Receives 'Hold' Rating from Brokerages

The medical equipment provider's stock has a consensus recommendation and average price target from analysts.

Mar. 13, 2026 at 2:48pm

Got story updates? Submit your updates here. ›

NovoCure Limited (NASDAQ:NVCR) has received a consensus 'Hold' rating from the seven research firms currently covering the company, according to MarketBeat. One analyst has a 'Sell' rating, three have 'Hold' ratings, and three have 'Buy' ratings on the stock. The average 12-month price target among the analysts is $26.93.

Why it matters

NovoCure is a global oncology company pioneering a novel cancer treatment called Tumor Treating Fields (TTFields), which delivers low-intensity electric fields to disrupt cancer cell division. The mixed analyst views on the stock reflect the ongoing challenges and uncertainties around the commercial adoption of this new therapy approach.

The details

Several equity research analysts have weighed in on NovoCure's stock recently. Wedbush maintained a 'Neutral' rating and $18 price target, while HC Wainwright raised its price target from $47 to $49 and reiterated a 'Buy' rating. Weiss Ratings also kept a 'Sell' rating on the shares, and Evercore set a $20 price objective.

  • NovoCure reported its latest quarterly results on February 26, 2026.

The players

NovoCure Limited

A global oncology company pioneering a novel cancer treatment called Tumor Treating Fields (TTFields), which delivers low-intensity electric fields to disrupt cancer cell division.

Wedbush

An equity research firm that maintained a 'Neutral' rating and $18 price target on NovoCure's stock.

HC Wainwright

An equity research firm that raised its price target on NovoCure's stock from $47 to $49 and reiterated a 'Buy' rating.

Weiss Ratings

An equity research firm that kept a 'Sell' rating on NovoCure's shares.

Evercore

An equity research firm that set a $20 price objective on NovoCure's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The mixed analyst views on NovoCure's stock reflect the ongoing challenges and uncertainties around the commercial adoption of its novel Tumor Treating Fields cancer therapy. As a pioneering approach, NovoCure's success will depend on demonstrating the long-term clinical and cost-effectiveness of its technology to both the medical community and patients.